Coastline Trust Co raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 46.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,985 shares of the biopharmaceutical company’s stock after buying an additional 2,860 shares during the quarter. Coastline Trust Co’s holdings in Gilead Sciences were worth $728,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. Garde Capital Inc. acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth $675,000. Archford Capital Strategies LLC grew its holdings in shares of Gilead Sciences by 5,400.0% during the 3rd quarter. Archford Capital Strategies LLC now owns 4,125 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 4,050 shares in the last quarter. Robinson Value Management Ltd. grew its holdings in shares of Gilead Sciences by 5.0% during the 3rd quarter. Robinson Value Management Ltd. now owns 22,482 shares of the biopharmaceutical company’s stock worth $1,821,000 after purchasing an additional 1,070 shares in the last quarter. Americafirst Capital Management LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter worth $658,000. Finally, EagleClaw Capital Managment LLC lifted its position in shares of Gilead Sciences by 17.0% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 22,025 shares of the biopharmaceutical company’s stock worth $1,776,000 after buying an additional 3,200 shares during the last quarter. 75.84% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently weighed in on GILD shares. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. BMO Capital Markets restated a “hold” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Friday, October 20th. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and dropped their price objective for the stock from $88.80 to $76.00 in a research report on Tuesday, January 30th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price objective for the company. in a research report on Wednesday, January 17th. Finally, Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $86.56.

In related news, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the sale, the executive vice president now directly owns 70,988 shares in the company, valued at $5,298,544.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.56, for a total value of $4,178,000.00. Following the sale, the chairman now owns 3,046,766 shares in the company, valued at $254,587,766.96. The disclosure for this sale can be found here. Insiders have sold 358,333 shares of company stock worth $28,066,908 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $79.32 on Monday. The stock has a market capitalization of $103,590.00, a P/E ratio of 22.79, a P/E/G ratio of -1.75 and a beta of 1.22. The company has a current ratio of 3.55, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. Gilead Sciences’s quarterly revenue was down 18.7% compared to the same quarter last year. During the same period last year, the company posted $2.70 earnings per share. research analysts forecast that Gilead Sciences, Inc. will post 6.41 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a dividend of $0.57 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. This represents a $2.28 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date is Thursday, March 15th. Gilead Sciences’s dividend payout ratio (DPR) is 59.77%.

COPYRIGHT VIOLATION WARNING: “Coastline Trust Co Raises Holdings in Gilead Sciences, Inc. (GILD)” was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://theolympiareport.com/2018/02/12/coastline-trust-co-raises-holdings-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.